Ftse Mib
33.675,15
0,00%
DAX
18.254,18
1,03%
S&P 500
5.473,17
-0,25%
NASDAQ
17.721,59
-0,79%
Bitcoin
64.680,30
-0,22%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Pacira BioSciences Inc (PCRX) Pacira BioSciences Inc (PCRX) Notizie

PCRX

Pacira BioSciences (PCRX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PCRX
DataOraFonteTitoloSimboloCompagnia
14/06/202400:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PCRXPacira BioSciences Inc
13/06/202423:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PCRXPacira BioSciences Inc
13/06/202416:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PCRXPacira BioSciences Inc
30/05/202414:00GlobeNewswire Inc.Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare ConferenceNASDAQ:PCRXPacira BioSciences Inc
10/05/202413:00GlobeNewswire Inc.Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029NASDAQ:PCRXPacira BioSciences Inc
08/05/202422:05GlobeNewswire Inc.Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior NotesNASDAQ:PCRXPacira BioSciences Inc
07/05/202422:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PCRXPacira BioSciences Inc
07/05/202422:00GlobeNewswire Inc.Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase programNASDAQ:PCRXPacira BioSciences Inc
07/05/202414:00GlobeNewswire Inc.Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:PCRXPacira BioSciences Inc
30/04/202414:00GlobeNewswire Inc.Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024NASDAQ:PCRXPacira BioSciences Inc
02/04/202414:00GlobeNewswire Inc.Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:PCRXPacira BioSciences Inc
13/03/202412:00GlobeNewswire Inc.Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the KneeNASDAQ:PCRXPacira BioSciences Inc
06/03/202414:00GlobeNewswire Inc.Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare ConferenceNASDAQ:PCRXPacira BioSciences Inc
29/02/202421:33Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PCRXPacira BioSciences Inc
29/02/202414:00GlobeNewswire Inc.Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial ResultsNASDAQ:PCRXPacira BioSciences Inc
22/02/202414:00GlobeNewswire Inc.Pacira to Report 2023 Financial Results on Thursday February 29, 2024NASDAQ:PCRXPacira BioSciences Inc
15/02/202414:36GlobeNewswire Inc.Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After BunionectomyNASDAQ:PCRXPacira BioSciences Inc
07/02/202414:00GlobeNewswire Inc.Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.NASDAQ:PCRXPacira BioSciences Inc
01/02/202416:45PR Newswire (US)G.O.A.T. Bowl I Registration Open to 4 Additional Pickleball TeamsNASDAQ:PCRXPacira BioSciences Inc
04/01/202423:18Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PCRXPacira BioSciences Inc
04/01/202423:00GlobeNewswire Inc.Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 RevenuesNASDAQ:PCRXPacira BioSciences Inc
03/01/202414:00GlobeNewswire Inc.Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:PCRXPacira BioSciences Inc
21/12/202313:30GlobeNewswire Inc.Pacira Appoints Frank D. Lee as Chief Executive OfficerNASDAQ:PCRXPacira BioSciences Inc
10/11/202313:30GlobeNewswire Inc.Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block IndicationsNASDAQ:PCRXPacira BioSciences Inc
07/11/202314:00GlobeNewswire Inc.Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in NovemberNASDAQ:PCRXPacira BioSciences Inc
02/11/202313:00GlobeNewswire Inc.Pacira BioSciences Reports Third Quarter 2023 Financial ResultsNASDAQ:PCRXPacira BioSciences Inc
26/10/202314:00GlobeNewswire Inc.Pacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023NASDAQ:PCRXPacira BioSciences Inc
12/10/202314:00GlobeNewswire Inc.American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc.NASDAQ:PCRXPacira BioSciences Inc
10/10/202314:00GlobeNewswire Inc.Pacira BioSciences Appoints Four New Independent Directors to its Board of DirectorsNASDAQ:PCRXPacira BioSciences Inc
02/10/202314:00GlobeNewswire Inc.American Society of Anesthesiologists and Pacira BioSciences, Inc. Announce New Grant to Advance Education and Enhance Patient CareNASDAQ:PCRXPacira BioSciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PCRX

La tua Cronologia

USOTC
SNMCY
Suncorp (PK)
USOTC
SMTEF
Smart Eye Aktiebolag (PK)
EU
ETAGI
Rep Fse 05 55 O A T
LSE
JPSL
LSE
YX45
Lloyds Bk.27
BIT
UB26F5
UniCredit Bank
AMEX
AEON.WS
AEON Biopharma
ASX
GEAR
BetaShares Geared Austra...
AMEX
SVY.X
LSE
TB49
Citi Fun 27
LSE
LAN
Land Of Leather
COIN
RIOCUSD
TSXV
BAG
Blende Silver
TG
BPC
Timber Pharmaceuticals
TSXV
SPDR
Spyder Cannabis
USOTC
ADTLF
Adriatic Metals (PK)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network